Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Executive Summary
Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.
You may also be interested in...
Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.
Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.
Nektar Edges Into Immunotherapy With Better Interleukin-2 Drug
Building on foundation of IL-2 inhibition in immunotherapy, Nektar introduces an improved stimulatory cytokine available on outpatient basis, NKTR-214, for a number of tumor types.